Cargando…

Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate

OBJECTIVE: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A 12-month, open-label safety study with SDX/d-MPH in children with ADHD showed that SDX/d-MPH was well tolerated and comparab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Childress, Ann C., Cutler, Andrew J., Patel, Maitrey, Oh, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254966/ https://www.ncbi.nlm.nih.gov/pubmed/37204277 http://dx.doi.org/10.1089/cap.2023.0012

Ejemplares similares

Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder
por: Mattingly, Greg W., et al.
Publicado: (2023)

Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study
por: Childress, Ann C., et al.
Publicado: (2023)

Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder
por: Braeckman, Rene, et al.
Publicado: (2022)

Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder
por: Liu, Feng, et al.
Publicado: (2006)

The Safety and Efficacy of Methylphenidate and Dexmethylphenidate in Adults with Attention Deficit/Hyperactivity Disorder
por: Sopko, Michael A., et al.
Publicado: (2010)

Chromatographic reversed HPLC and TLC-densitometry methods for simultaneous determination of serdexmethylphenidate and dexmethylphenidate in presence of their degradation products—with computational assessment
por: Kelani, Khadiga M., et al.
Publicado: (2023)

Gender Effects in the Efficacy of Racemic Amphetamine Sulfate in Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2019)

Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting
por: Childress, Ann C., et al.
Publicado: (2017)

Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study
por: Childress, Ann C., et al.
Publicado: (2020)

Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2020)

Severe muscle pain and stiffness due to dexmethylphenidate
por: Kon, Jacob J., et al.
Publicado: (2020)

Dexmethylphenidate-Induced Rhabdomyolysis by Interaction With Aromatase Inhibitor
por: Huang, Derrick, et al.
Publicado: (2022)

Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study
por: Cutler, Andrew J., et al.
Publicado: (2022)

Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study
por: Schein, Jeff, et al.
Publicado: (2022)

Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study
por: Schein, Jeff, et al.
Publicado: (2022)

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder
por: Wigal, Sharon B, et al.
Publicado: (2009)

Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2018)

d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial
por: Cutler, Andrew J., et al.
Publicado: (2023)

Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”
por: Nasser, Azmi, et al.
Publicado: (2022)

Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day
por: Wigal, Sharon B, et al.
Publicado: (2010)

Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder
por: Wigal, Sharon B., et al.
Publicado: (2017)

Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control study
por: Schein, Jeff, et al.
Publicado: (2023)

The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study
por: Childress, Ann C., et al.
Publicado: (2015)

Management of attention-deficit hyperactivity disorder
por: Verma, Rohit, et al.
Publicado: (2011)

The history of attention deficit hyperactivity disorder
por: Lange, Klaus W., et al.
Publicado: (2010)

Stigma in attention deficit hyperactivity disorder
por: Mueller, Anna K., et al.
Publicado: (2012)

Attention Deficit Hyperactivity Disorder and Athletes
por: White, Russell D., et al.
Publicado: (2014)

Driving and attention deficit hyperactivity disorder
por: Fuermaier, Anselm B. M., et al.
Publicado: (2015)

Genetics of attention deficit hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2018)

Neuroimaging in attention-deficit/hyperactivity disorder
por: Pereira-Sanchez, Victor, et al.
Publicado: (2021)

Attention-deficit/hyperactive disorder updates
por: Kessi, Miriam, et al.
Publicado: (2022)

Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States – a retrospective claims analysis
por: Schein, Jeff, et al.
Publicado: (2022)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day
por: Faraone, Stephen V., et al.
Publicado: (2023)

Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Newcorn, Jeffrey H., et al.
Publicado: (2017)

Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2019)

Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder
por: Owens, Judith, et al.
Publicado: (2016)

Treatment Patterns Among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis
por: Schein, Jeff, et al.
Publicado: (2023)

Attention deficit hyperactivity disorder (ADHD) & COVID-19: Attention deficit hyperactivity disorder: Consequences of the 1st wave
por: Insa, I., et al.
Publicado: (2021)

Attention deficit hyperactivity disorder in adults who present with self-harm: a comparative 6-month follow-up study
por: Olsson, Petter, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u69tuo51jq03fsgthnvcogi80f